{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-318469","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.240224+00:00","generated_at":"2026-05-16T13:16:17.226293+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome","bullets":["Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).","Trial KYSA-8 evaluates fully human autologous CD19 CAR T-cell therapy with CD28 co-stimulation.","Company to host conference call on Dec 15, 2025 at 8:00 AM ET to discuss results."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-318469","json":"https://secwatch.observer/filing/0001193125-25-318469.json","markdown":"https://secwatch.observer/filing/0001193125-25-318469.md","text":"https://secwatch.observer/filing/0001193125-25-318469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/0001193125-25-318469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/d33692d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:16:17.226293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}